Group 1 - YS Biopharma Co., Ltd. received a requisition from APEX Prospect Limited to convene an extraordinary general meeting (EGM) due to concerns regarding corporate governance and management practices [1][2] - The agenda for the EGM includes reaffirming the appointment of current board members, investigating alleged misconduct by former chairperson Mr. Yi Zhang, strengthening corporate governance, and removing Mr. Yi Zhang from all positions within the company [2][3] - The proposed EGM is scheduled for February 22, 2024, in Hong Kong, where shareholders will vote on the resolutions put forth by the requisitioning shareholder [3] Group 2 - YS Biopharma is focused on developing vaccines and therapeutic biologics for infectious diseases and cancer, utilizing its proprietary PIKA® immunomodulating technology platform [4] - The company operates in multiple countries, including China, the United States, Singapore, and the Philippines, and is led by a management team with extensive experience in the biopharmaceutical industry [4]
YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate Governance